HIV-Treatment-focused giant Gilead Sciences, Inc. (NASDAQ:GILD) is scheduled to report fourth-quarter and full-year 2024 results on February 11, after the market close.
Analysts estimate fourth-quarter adjusted EPS of $1.70 and revenues of $7.14 billion. The Wall Street forecasts fiscal year 2024 adjusted EPS of $4.41 and sales of $28.31 billion.
Gilead reported third-quarter adjusted EPS of $2.02, down from $2.29 a year ago, beating the consensus of $1.55.
Also Read: Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
The HIV drug maker reported third-quarter sales of $7.55 billion, up 7% year over year, beating the consensus of $7 billion, primarily due to higher sales in HIV and Veklury (remdesivir), Oncology, and Liver Disease.
Gilead will report the first full quarter sales from Livdelzi (seladelpar) after gaining FDA accelerated approval in mid-August 2024 for primary biliary cholangitis.
In October, Gilead Sciences announced plans to voluntarily withdraw the U.S. accelerated approval for Trodelvy (sacituzumab govitecan-hziy; SG) for adult patients with locally advanced or metastatic urothelial cancer who have previously received platinum-containing chemotherapy and either programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.
In January, Gilead Sciences and LEO Pharma announced a strategic partnership to accelerate the development and commercialization of LEO Pharma’s small molecule oral STAT6 for inflammatory diseases.
Gilead will acquire LEO Pharma’s comprehensive preclinical oral STAT6 small molecule inhibitors and targeted protein degraders.
Gilead will lead further development efforts for the oral programs, while LEO Pharma will lead the development of potential topical formulations of STAT6 inhibitors.
LEO Pharma can receive up to $1.7 billion, including an upfront payment of $250 million.
In addition, LEO Pharma may also receive tiered royalties ranging from the high single-digits to the mid-teens on sales of oral STAT6 products.
The transaction with LEO Pharma is expected to reduce Gilead’s GAAP and non-GAAP 2025 EPS by approximately $0.15 – $0.17.
Price Action: GILD stock is down 0.78% at $95.29 at last check Monday.
Read Next:
Photo via Shutterstock
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。